- Clinical-stage biotech developer CNS Pharmaceuticals is working to demonstrate the potential effectiveness of its novel drug, Berubicin, in treating aggressive and rare brain cancer glioblastoma multiforme (“GBM”)
- CNS expects to launch Phase II trials of Berubicin later this year or in Q1 of 2021, building on promising results shown in initial trials
- One patient in the Phase I trial has remained cancer-free over the course of 14 years, and 44 percent of the patients who could be evaluated experienced a clinically significant positive response to Berubicin
- CNS’s laser-focused strategy for developing a GBM therapy is also leading the company to prepare, through its sub-licensee partner WPD Pharmaceuticals, for a first-ever Phase I pediatric trial of Berubicin in Poland as well as continuing the development of the company’s second drug candidate, WP1244, which has shown tremendous promise in stopping cancer proliferation in preclinical studies comparing it to chemotherapy drug daunorubicin
CNS Pharmaceuticals (NASDAQ: CNSP) is building its technologically advanced strategy for demonstrating the potential brain tumor-fighting capabilities of its novel drug Berubicin, announcing recently an agreement with medical imaging company Image Analysis Group (“IAG”) to evaluate upcoming clinical phase II patient trial scansin real time.
IAG’s proprietary platform DYNAMIKA is an AI-driven technology developed to aid in the analysis of patient responses during pharmaceutical trial’s, and IAG has extensive experience in partnering with the biotech industry — oncology companies in particular — to provide a centralized reading of critical data, according to a news release about the partnership (https://nnw.fm/jwuoc).
CNS Pharmaceuticals is developing unique treatments for primary and metastatic cancers of the brain and central nervous system, including the company’s lead drug candidate Berubicin, which aims to treat the aggressive brain cancer glioblastoma multiforme (“GBM”) (https://nnw.fm/Prq8c).
“This drug was designed specifically to penetrate the Blood-Brain Barrier and to treat cancers in the brain, which we all know are extremely difficult given that the brain is the most privileged organ in the body,” CNS CEO John Climaco told attendees at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit as part of the company’s investment highlights presentation at the virtual conference Sept. 22 (https://nnw.fm/vmMql).
During a 2006 Phase I clinical trial, Berubicin “appeared to demonstrate one durable, complete response against GBM,” Climaco said. The specified patient has remained cancer-free as of the last assessment on Feb. 20 of this year. Twenty-seven of the participating patients were able to be evaluated, and 44 percent of them experienced a clinically significant improvement in condition as a result of the trial.
Regarding IAG’s scientific and clinical imaging expertise in the field of GBM and the prowess of the company’s analytical API, Climaco stated, “IAG has an exemplary track record of partnering closely with companies in the biotech space to provide critical analysis of both efficacy and patient response, which we believe will be pivotal in advancing our Berubicin clinical trials.”
IAG CEO Dr. Olga Kubassova stated the platform will not only help CNS analyze Berubicin’s effectiveness and build scientific evidence of its performance but will also help the company efficiently reduce development costs, uncertainties about outcomes and timelines for the product’s advancement.
In addition to the Berubicin trials, CNS and its partner WPD Pharmaceuticals are preparing for a first-ever Phase I Berubicin trial for pediatric patients who have brain cancer. CNS is also developing a second drug candidate, WP1244, shown in preclinical studies to have a DNA-binding agent 500 times more potent than chemotherapy drug daunorubicin in stopping tumor cell expansion.
“We are laser-focused as a company at this point on a critical unmet medical need, and that is the treatment of glioblastoma, which is the most aggressive, common and incurable form of brain cancer,” Climaco told conference attendees. “If you get glioblastoma, the devastating fact is you’re going to die from that disease. After decades without progress in the treatment of this terrible disease, we believe that Berubicin could potentially be a game-changer.”
For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://nnw.fm/CNSP
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
NetworkNewsWire is part of the InvestorBrandNetwork.
